{"id":"https://openalex.org/W1997695098","doi":"https://doi.org/10.1016/0304-3835(83)90041-1","title":"In vitro studies on potentiation of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa)","display_name":"In vitro studies on potentiation of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa)","publication_year":1983,"publication_date":"1983-09-01","ids":{"openalex":"https://openalex.org/W1997695098","doi":"https://doi.org/10.1016/0304-3835(83)90041-1","mag":"1997695098","pmid":"https://pubmed.ncbi.nlm.nih.gov/6199106"},"language":"en","primary_location":{"id":"doi:10.1016/0304-3835(83)90041-1","doi":"https://doi.org/10.1016/0304-3835(83)90041-1","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0304-3835(83)90041-1","pdf_url":null,"source":{"id":"https://openalex.org/S106234763","display_name":"Cancer Letters","issn_l":"0304-3835","issn":["0304-3835","1872-7980"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037835293","display_name":"Shoichi Yamamoto","orcid":"https://orcid.org/0000-0003-4833-5216","observed_orcids":["https://orcid.org/0000-0003-4833-5216"]},"institutions":[{"id":"https://openalex.org/I189996419","display_name":"Kawasaki Medical School","ror":"https://ror.org/059z11218","country_code":"JP","type":"education","lineage":["https://openalex.org/I189996419"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shoichi Yamamoto","raw_affiliation_strings":["Department of Urology, Kawasaki Medical School, Kurashiki 701-01 Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Kawasaki Medical School, Kurashiki 701-01 Japan","institution_ids":["https://openalex.org/I189996419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056921218","display_name":"Hiroyoshi Y. Tanaka","orcid":"https://orcid.org/0000-0003-1494-7716","observed_orcids":["https://orcid.org/0000-0003-1494-7716"]},"institutions":[{"id":"https://openalex.org/I189996419","display_name":"Kawasaki Medical School","ror":"https://ror.org/059z11218","country_code":"JP","type":"education","lineage":["https://openalex.org/I189996419"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroyoshi Tanaka","raw_affiliation_strings":["Department of Urology, Kawasaki Medical School, Kurashiki 701-01 Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Kawasaki Medical School, Kurashiki 701-01 Japan","institution_ids":["https://openalex.org/I189996419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111794545","display_name":"Toshinori Kanamori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165085132","display_name":"Mochida Pharmaceutical (Japan)","ror":"https://ror.org/045p8e908","country_code":"JP","type":"company","lineage":["https://openalex.org/I165085132"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshinori Kanamori","raw_affiliation_strings":["Mochida Pharmaceutical Co. Ltd., 1-1-1 Kamiya, Tokyo 115 Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mochida Pharmaceutical Co. Ltd., 1-1-1 Kamiya, Tokyo 115 Japan","institution_ids":["https://openalex.org/I165085132"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074546199","display_name":"Masahiro Nobuhara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165085132","display_name":"Mochida Pharmaceutical (Japan)","ror":"https://ror.org/045p8e908","country_code":"JP","type":"company","lineage":["https://openalex.org/I165085132"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masahiro Nobuhara","raw_affiliation_strings":["Mochida Pharmaceutical Co. Ltd., 1-1-1 Kamiya, Tokyo 115 Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mochida Pharmaceutical Co. Ltd., 1-1-1 Kamiya, Tokyo 115 Japan","institution_ids":["https://openalex.org/I165085132"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109173342","display_name":"Masayoshi Namba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189996419","display_name":"Kawasaki Medical School","ror":"https://ror.org/059z11218","country_code":"JP","type":"education","lineage":["https://openalex.org/I189996419"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masayoshi Namba","raw_affiliation_strings":["Department of Pathology, Kawasaki Medical School, Kurashiki 701-01, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Kawasaki Medical School, Kurashiki 701-01, Japan","institution_ids":["https://openalex.org/I189996419"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4960,"currency":"USD","value_usd":4960},"apc_paid":null,"fwci":0.612,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.65021087,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"20","issue":"2","first_page":"131","last_page":"138"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00800000037997961,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.007300000172108412,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon","display_name":"interferon","score":0.781000018119812},{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.6959999799728394},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.75},{"id":"https://openalex.org/keywords/drug-potentiation","display_name":"drug potentiation","score":0.9290000200271606},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.609000027179718},{"id":"https://openalex.org/keywords/hela-cells","display_name":"HeLa cells","score":0.9399999976158142},{"id":"https://openalex.org/keywords/cervical-cancer","display_name":"cervical cancer","score":0.8840000033378601},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.8299999833106995},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5289999842643738},{"id":"https://openalex.org/keywords/peplomycin","display_name":"peplomycin","score":0.6639999747276306},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.7440000176429749},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.8500000238418579},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.777999997138977},{"id":"https://openalex.org/keywords/nimustine","display_name":"ACNU","score":0.5630000233650208},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":0.6710000038146973},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.7490000128746033},{"id":"https://openalex.org/keywords/metabolic-antagonists","display_name":"metabolic antagonists","score":0.5659999847412109},{"id":"https://openalex.org/keywords/antibiotics","display_name":"antibiotics","score":0.5299999713897705},{"id":"https://openalex.org/keywords/cell-proliferation-inhibition","display_name":"cell proliferation inhibition","score":0.5090000033378601}],"concepts":[{"id":"https://openalex.org/C2777366897","wikidata":"https://www.wikidata.org/wiki/Q847482","display_name":"HeLa","level":3,"score":0.6756854057312012},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6524286866188049},{"id":"https://openalex.org/C2780847677","wikidata":"https://www.wikidata.org/wiki/Q4674302","display_name":"Aclarubicin","level":4,"score":0.5944268703460693},{"id":"https://openalex.org/C2779338040","wikidata":"https://www.wikidata.org/wiki/Q19856779","display_name":"Mitomycin C","level":2,"score":0.5845623016357422},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5524297952651978},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.534213662147522},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4789619743824005},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.4771425426006317},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.47376731038093567},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.45394590497016907},{"id":"https://openalex.org/C113842279","wikidata":"https://www.wikidata.org/wiki/Q1873857","display_name":"Lymphoblast","level":3,"score":0.44171181321144104},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.4383700489997864},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.43432891368865967},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.41262468695640564},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3789832592010498},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3749024569988251},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.283513605594635},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.21466940641403198},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2001594603061676},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.16189301013946533},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000477","descriptor_name":"Alkylating Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000903","descriptor_name":"Antibiotics, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006367","descriptor_name":"HeLa Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/0304-3835(83)90041-1","doi":"https://doi.org/10.1016/0304-3835(83)90041-1","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0304-3835(83)90041-1","pdf_url":null,"source":{"id":"https://openalex.org/S106234763","display_name":"Cancer Letters","issn_l":"0304-3835","issn":["0304-3835","1872-7980"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Letters","raw_type":"journal-article"},{"id":"pmid:6199106","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6199106","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer letters","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320320912","display_name":"Ministry of Education, Culture, Sports, Science and Technology","ror":"https://ror.org/048rj2z13"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W389518503","https://openalex.org/W1589608483","https://openalex.org/W1978606578","https://openalex.org/W1995578078","https://openalex.org/W1996549520","https://openalex.org/W1999087217","https://openalex.org/W1999867700","https://openalex.org/W2018162474","https://openalex.org/W2084929520","https://openalex.org/W2122448855","https://openalex.org/W2138039307","https://openalex.org/W2169163372","https://openalex.org/W2269595883","https://openalex.org/W2412426252","https://openalex.org/W2415299230","https://openalex.org/W3216705818","https://openalex.org/W6649908866"],"related_works":["https://openalex.org/W1967658581","https://openalex.org/W2084929520","https://openalex.org/W1545320152","https://openalex.org/W389518503","https://openalex.org/W2317769951","https://openalex.org/W2086961298","https://openalex.org/W22400421","https://openalex.org/W2411893293","https://openalex.org/W2112349893","https://openalex.org/W2419170672"],"abstract_inverted_index":null,"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}